Press Releases

05.03.2022

Pfizer Reports First-Quarter 2022 Results

04.28.2022

Pfizer Announces 2022 Shareholder Meeting Preliminary Results

04.28.2022

Pfizer Declares Second-Quarter 2022 Dividend

04.27.2022

Pfizer and Biohaven’s VYDURA® (Rimegepant) Granted First Ever Marketing Authorization by European Commission for Both Acute Treatment of Migraine and Prophylaxis of Episodic Migraine

04.26.2022

Valneva and Pfizer Report Positive Phase 2 Pediatric Data for Lyme Disease Vaccine Candidate

04.19.2022

Pfizer Invites Shareholders to Attend Virtual-Only 2022 Annual Meeting of Shareholders on April 28

04.14.2022

Pfizer and BioNTech Announce Data Demonstrating High Immune Response Following a Booster Dose of their COVID-19 Vaccine in Children 5 Through 11 Years of Age

04.12.2022

Myovant Sciences and Pfizer Provide Update on Supplemental New Drug Application for MYFEMBREE® for the Management of Moderate to Severe Pain Associated with Endometriosis

04.11.2022

Pfizer Names David M. Denton Chief Financial Officer

04.07.2022

Pfizer to Acquire ReViral and Its Respiratory Syncytial Virus Therapeutic Candidates

03.29.2022

Pfizer and BioNTech Receive Expanded U.S. Emergency Use Authorization for an Additional COVID-19 Vaccine Booster in Individuals Aged 50 Years and Older

03.29.2022

Pfizer Announces Positive Top-line Results from Yearlong Phase 3 Trial of Etrasimod in Ulcerative Colitis, Underscoring Best-in-Class Potential